Citations

Clear

1446 citation(s) found for "Howard, F".

The Relationship between Croup and Gastroesophageal Reflux: A Systematic Review and Meta‐Analysis
Coughran, Alanna, Balakrishnan, Karthik , Vaezeafshar, Reza, Capdarest‐Arest, Nicole , Hamdi, Osama A. , Sidell, Douglas R. , Sidell, Douglas R. , Capdarest-Arest, Nicole , Hamdi, Osama , Sidell, Douglas R , Sidell, Douglas R , Balakrishnan, Karthik , Ma, Yifei

Mayo Clinic

The Laryngoscope | February 10, 2020 | Volume: 131 | Issue: 1 | Pages: 209-217

10.1002/lary.28544 | PMID 32040207 Get It

ObjectiveThe mechanism by which recurrent croup occurs is unknown. Gastroesophageal reflux is commonly implicated, although this relationship is only loosely documented. We conducted a systematic review with a meta‐analysis component to evaluate the relationship between recurrent croup and gastroesophageal reflux disease (GERD), and to assess for evidence of improvement in croup symptoms when treated.Style DesignSystematic Review and Meta Analysis.MethodsWe searched five separate databases. Studies were included if they discussed the relationship between croup and GERD in children, >5 subjects, and available in English. Literature retrieved was assessed according to pre‐specified criteria. Retrieved articles were reviewed by two independent authors and decisions mediated by a third author. If there was a difference of opinion after first review, a second review was performed to obtain consensus. Heterogeneity was calculated and summarized in forest plots.ResultsOf 346 initial records, 15 met inclusion criteria. These were two retrospective cohort and 13 cross‐sectional studies. Thirteen of 15 articles support an association between recurrent croup and GERD. Although heterogeneity is high among studies that reported prevalence of GERD, there is less uncertainty in results for improvement to recurrent croup after GERD treatment. Most studies lacked a control group and all carry a moderate‐to‐high risk of bias.ConclusionThere is limited evidence linking GERD to recurrent croup; Further research is needed to assess for causality as most studies are retrospective, lack a control group, and have a study design exposing them to bias. Patients treated with reflux medication appear to demonstrate a reduced incidence of croup symptoms.Level of Evidence1 Laryngoscope, 131:209–217, 2021
Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial
Khoudary, Samar R. El , Venugopal, Vidya, Black, Dennis M. , HARMAN, MITCHELL S., Hodis, Howard N., Miller, Virginia M. , Taylor, Hugh S. , Budoff, Matthew J. , El Khoudary, Samar R , Budoff, Matthew , Manson, JoAnn E. , Brooks, Maria M. , Santoro, Nanette F. , Naftolin, Frederick , Brinton, Eliot A.

Mayo Clinic

Menopause | February 6, 2020 | Volume: 27 | Issue: 3 | Pages: 255-262

10.1097/gme.0000000000001472 | PMID 32015261 Get It

Abstract Objective: Heart fat deposition has been linked to atherosclerosis, and both accelerate after menopause. Hormone therapy (HT) may differentially slow heart fat deposition and progression of atherosclerosis, depending on the specific HT agent or its route of administration. Our objective was to evaluate the effects of different HT agents, oral and transdermal, on associations between heart fat accumulation and atherosclerosis progression, measured by carotid intima-media thickness (CIMT), in recently menopausal women from the Kronos Early Estrogen Prevention Study (KEEPS) trial. Methods: KEEPS was a randomized, placebo-controlled trial of the effects of 0.45 mg/d oral conjugated equine estrogens (o-CEE) or 50 mcg/d transdermal 17β-estradiol (t-E 2 ), compared with placebo, on 48 months progression of CIMT. Epicardial adipose tissue (EAT) and paracardial adipose tissue (PAT) volumes were quantified by computed tomography. Results: In all, 467 women (mean age [SD] 52.7 [2.5]; 78.2% White; 30% on o-CEE, 30.8% t-E 2 , 39.2% placebo) with heart fat volumes and CIMT at baseline and 48 months were included. EAT and PAT changes were not associated with CIMT progression; however, the assigned treatment significantly modified the association between PAT (but not EAT) change and CIMT progression. In the o-CEE group, adjusted CIMT progression was 12.66 μm (95% confidence interval [CI] 1.80, 23.52) lower than in t-E 2 group ( P = 0.02), and 10.09 μm (95% CI 0.79, 19.39) lower than in placebo group ( P = 0.03), as per 1-SD increase in PAT. Conclusion: Compared with t-E 2 , o-CEE appears to slow down the adverse effect of increasing PAT on progression of atherosclerosis. Whether this beneficial association is specific to CEE or to the oral route of CEE administration is unclear and should be assessed further.
The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females
Chen, Yanxia , Moutal, Aubin , Navratilova, Edita , Kopruszinski, Caroline Machado , Yue, Xu , Ikegami, Megumi , Chow, Michele , Kanazawa, Iori , Bellampalli, Shreya S. , Xie, Jennifer Y. , Patwardhan, Amol , Fields, Howard L. , Neugebauer, Volker , Kopruszinski, Caroline , Xie, Jennifer , Fields, Howard , Dodick, David, Khanna, Rajesh , Porreca, Frank , Navratilova, Edita , Rice, Kenner C. , Akopian, Armen N. , Dodick, David W. , Khanna, Rajesh , Porreca, Frank

Mayo Clinic

Science Translational Medicine | February 5, 2020 | Volume: 12 | Issue: 529 | Pages: No page available

10.1126/scitranslmed.aay7550 | PMID 32024801 Get It

Female selective nociceptor sensitization and opioid-induced hyperalgesia result from an imbalance of prolactin receptor isoforms.
Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.
Safran, Howard , Dhawan, Mallika , Souza, André Luiz de , Powell, Steven , Billadeau, Daniel D. , Carneiro, Benedito A. , Cavalcante, Ludimila , Giles, Francis Joseph , Münster, Pamela N.

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 827-827

10.1200/jco.2020.38.4_suppl.827 Get It

827 Background: 9-ING-41 is a selective GSK-3β inhibitor with significant pre-clinical antitumor activity in a broad spectrum of malignancies as a single agent and in combination with cytotoxic agents. GSK-3β is a serine/threonine kinase whose overexpression is associated with advanced stage, aggressive tumor growth, and chemotherapy resistance. We report the preliminary results of patients (pts) with gastrointestinal (GI) malignancies. Methods: Phase 1b/2 study evaluating safety and efficacy of 9-ING-41 as monotherapy and combination therapy in pts with refractory cancers. 9-ING-41 is administered intravenously twice-weekly as a single agent (21-day-cycle) or combined with chemotherapy agents, including gemcitabine (GEM), nab-paclitaxel + GEM, carboplatin, or paclitaxel. Study parts 1 and 2 evaluate the safety, describe dose-limiting toxicities (DLTs), determine the maximum tolerated dose and the recommended phase 2 study dose (RP2D) for 9-ING-41 as monotherapy (Part 1) and as combination therapy (Part 2). Part 3 (Simon 2-Stage Phase 2) assess clinical benefit in pts treated with 9-ING-41-based combinations at the RP2D established in Part 2. Response is assessed by RECIST 1.1 criteria in the evaluable lesions. Results: To date, the study accrued 63 pts. Five dose levels (1, 2, 3.3, 5 and 7 mg/kg) have been completed without DLTs. Part 2 of the study evaluating 9-ING-41-based chemotherapy combinations is ongoing. Five out of nine pts with pancreas cancer (PCa) enrolled had stable disease (SD) as the best response; 2 out of 9 pts had a 40-45% decline of CA 19-9. One pt completed 6 cycles with 9-ING-41, two pts completed 4 cycles with 9-ING-41/GEM. Two active pts are receiving 9-ING-41/GEM with SD after 3 and 4 cycles. Three out of four pts with adenocarcinoma of the appendix enrolled had SD as the best response; two pts in active treatment are receiving cycles 5 and 6. One out of 13 pts with colorectal cancer had SD. 9-ING-41-attributable AE to date are reversible grade 1 transient visual changes (color perception). Conclusions: 9-ING-41 is well-tolerated with encouraging SD among heavily pretreated pts with carcinoma of the pancreas and appendix. Clinical trial information: NCT03678883.
Early detection and imaging strategies to reveal and target developing pancreatic cancer
Wallace, Michael B. , Störz, Peter , Wallace, Michael B , Crawford, Howard C.

Mayo Clinic

Expert Review of Anticancer Therapy | January 27, 2020 | Volume: 20 | Issue: 2 | Pages: 81-83

10.1080/14737140.2020.1720654 | PMID 31986932 Get It

American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
Chou, Stella T. , Alsawas, Mouaz , Fasano, Ross M. , Field, Joshua J. , Howard, Jo , Kameka, Michelle , Kwiatkowski, Janet L. , Pirenne, France , Shi, Patricia A. , Westhoff, Connie M. , Wong, Trisha E. , Alsawas, Mouaz , Shi, Patricia A , Hendrickson, Jeanne E. , Stowell, Sean R. , Thein, Swee Lay , Akl, Elie A.

Mayo Clinic

Blood Advances | January 27, 2020 | Volume: 4 | Issue: 2 | Pages: 327-355

10.1182/bloodadvances.2019001143 | PMID 31985807 Get It

Abstract In July 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired. Background: Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes. Objective: Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications. Methods: The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment. Results: The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload. Conclusions: The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head
Abrams, Ross A. , Winter, Kathryn, Safran, Howard , Regine, William F., Berger, Adam C. , Gillin, Michael T. , Lowy, Andrew M. , DiPetrillo, Thomas A., Corn, Benjamin W. , Seaward, Samantha A. , Haddock, Michael G. , Song, Suisui, Jiang, Yixing , Fisher, Barbara J., Mehta, Sharmila, Willett, Christopher G. , Crane, Christopher H. , Seaward, Samantha A , Goodman, Karyn A. , Philip, Philip A. , Wu, Abraham J , Katz, Alan W.

Mayo Clinic

American Journal of Clinical Oncology | January 27, 2020 | Volume: 43 | Issue: 3 | Pages: 173-179

10.1097/coc.0000000000000633 | PMID 31985516 Get It

Purpose: NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. Methods: Eligibility—within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180. Gemcitabine arm—6 cycles of gemcitabine. Gemcitabine+erlotinib arm—gemcitabine and erlotinib 100 mg/d. Two hundred deaths provided 90% power (1-sided α=0.15) to detect the hypothesized OS signal (hazard ratio=0.72) in favor of the arm 2. Results: From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2. Median age was 63 (39 to 86) years. CA19-9 ≤90 in 93%. Arm 1: 32 patients (20%) grade 4 and 2 (1%) grade 5 adverse events; arm 2, 27 (17%) grade 4 and 3 (2%) grade 5. GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, ( P =0.22). The median follow-up (surviving patients) was 42.5 months (min-max: <1 to 75). With 203 deaths, the median and 3-year OS (95% confidence interval) are 29.9 months (21.7, 33.4) and 39% (30, 45) for arm 1 and 28.1 months (20.7, 30.9) and 39% (31, 47) for arm 2 (log-rank P =0.62). Hazard ratio (95% confidence interval) comparing OS of arm 2 to arm 1 is 1.04 (0.79, 1.38). Conclusions: The addition of adjuvant erlotinib to gemcitabine did not provide a signal for increased OS in this trial.
Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Ducharme, Simon , Dols, Annemiek , Laforce, Robert , Devenney, Emma , Kumfor, Fiona , Stock, Jan Van den , Dallaire‐Théroux, Caroline , Seelaar, Harro , Gossink, Flora , Vijverberg, Everard G.B. , Huey, Edward D. , Vandenbulcke, Mathieu , Trieu, Calvin , Onyike, Chiadi U. , Souza, Leonardo Cruz de , Santillo, Alexander , Waldö, Maria Landqvist , Landín-Romero, Ramón , Piguet, Olivier , Kelso, Wendy , Eratne, Dhamidhu , Ikeda, Manabu , Perry, David C. , Pressman, Peter , Vandenberghe, Rik , Mendez, Mario F. , Azuar, Carole, Lévy, Richard, Ber, Isabelle Le , Lerner, Alan J. , Ellajosyula, Ratnavalli , Galimberti, Daniela , Hornberger, Michael , Rosen, Howard J. , Hodges, John R. , Diehl‐Schmid, Janine , Pijnenburg, Yolande A.L. , Galimberti, Daniela , Pijnenburg, Yolande A L , Seelaar, Harro , Vandenberghe, Rik , Laforce, Robert , Masellis, Mario , Caramelli, Paulo , Velakoulis, Dennis , Boeve, Bradley F. , Báez, Sandra , Pasquier, Florence , Scarpini, Elio , Swieten, John C. van

Mayo Clinic

Brain | January 16, 2020 | Volume: 143 | Issue: 6 | Pages: 1632-1650

10.1093/brain/awaa018 | PMID 32129844 Get It

Abstract The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset dementia. The diagnosis of bvFTD remains challenging because of the limited accuracy of neuroimaging in the early disease stages and the absence of molecular biomarkers, and therefore relies predominantly on clinical assessment. BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders. To date, ∼50% of patients with bvFTD receive a prior psychiatric diagnosis, and average diagnostic delay is up to 5–6 years from symptom onset. It is also not uncommon for patients with primary psychiatric disorders to be wrongly diagnosed with bvFTD. The Neuropsychiatric International Consortium for Frontotemporal Dementia was recently established to determine the current best clinical practice and set up an international collaboration to share a common dataset for future research. The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment. A systematic literature search with a narrative review was performed to determine all bvFTD-related diagnostic evidence for the following topics: bvFTD history taking, psychiatric assessment, clinical scales, physical and neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural neuroimaging, functional neuroimaging, CSF and genetic testing. For each topic, responsible team members proposed a set of minimal requirements, optimal clinical recommendations, and tools requiring further research or those that should be developed. Recommendations were listed if they reached a ≥ 85% expert consensus based on an online survey among all consortium participants. New recommendations include performing at least one formal social cognition test in the standard neuropsychological battery for bvFTD. We emphasize the importance of 3D-T1 brain MRI with a standardized review protocol including validated visual atrophy rating scales, and to consider volumetric analyses if available. We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD when normal, whereas non-specific regional metabolism abnormalities should not be over-interpreted in the case of a psychiatric differential diagnosis. We highlight the potential role of serum or CSF neurofilament light chain to differentiate bvFTD from primary psychiatric disorders. Finally, based on the increasing literature and clinical experience, the consortium determined that screening for C9orf72 mutation should be performed in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort
Heuer, Hilary W. , Wang, P., Rascovsky, Katya, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickerson, Brad C., Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff-Radford, N. R., Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kornak, John , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Ljubenkov, Peter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Rosen, Howard J. , Boxer, Adam L. , consortia, on behalf of the ARTFL and LEFFTDS, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Wolf, A., Appleby, Brian S. , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Litvan, Irene , Potter, M., Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 60-70

10.1002/alz.12046 | PMID 31914226 Get It

AbstractIntroductionBehavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments.MethodsA total of 135 sporadic (s‐bvFTD; mean age 63.3 years; 34% female) and 99 familial (f‐bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f‐bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule‐associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation.ResultsParticipants with f‐bvFTD were younger and had earlier age at onset. s‐bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI‐Q) scores due to more frequent endorsement of depression and irritability.Discussionf‐bvFTD and s‐bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
Miyagawa, Toji , Brushaber, Danielle , Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Forsberg, Leah K. , Heuer, Hilary W. , Kornak, John , Boxer, Adam L. , Rosen, Howard J. , Bordelon, Yvette , Bove, Jessica, Brannelly, Patrick , Caso, Christina, Coppola, Giovanni , Dever, Reilly, Dheel, Christina, Dickinson, Susan, Domínguez, S. Carbajal, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrell, Jessica, Fishman, Ann, Gavrilova, Ralitza H. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kraft, Ruth, Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Multani, Namita, Onyike, Chiadi U. , Padmanabhan, Jaya , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Kate, Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Toga, Arthur W. , Trojanowski, John Q. , Wang, Ping , Weıntraub, Sandra , Wong, Bonnie , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Knopman, David S. , Boeve, Bradley F. , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Kerwin, Diana , Litvan, Irene , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 106-117

10.1002/alz.12033 | PMID 31914218 Get It

AbstractIntroductionWe created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD.MethodsThe CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants.ResultsThe CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non‐fluent/agrammatic variant primary progressive aphasia participants.DiscussionThe global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.